Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of liraglutide on intracerebral amyloid deposition in Alzheimer's Disease.

Next Previous
Search
Trial Profile

Effects of liraglutide on intracerebral amyloid deposition in Alzheimer's Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics

Most Recent Events

  • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
  • 13 Jun 2017 Results of effect of liraglutide in terms of cerebral metabolic rate of glucose (n=38) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
  • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top